DRIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DarioHealth Corp (DRIO) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The company's financial performance is weak, with significant revenue and net income declines, and there are no positive catalysts or strong trading signals to justify immediate entry. The technical indicators are neutral, and hedge funds are selling the stock heavily. Therefore, it is better to hold off on investing in this stock at the moment.
The MACD is positive and expanding, indicating a potential upward momentum. RSI is neutral at 54.32, suggesting no clear overbought or oversold condition. Moving averages are converging, showing no strong trend direction. Key support is at 10.86, and resistance levels are at 11.984 and 12.33.
Gross margin increased by 15.30% YoY to 60.22%, showing some operational efficiency improvement.
Hedge funds are heavily selling the stock, with a 109.67% increase in selling activity over the last quarter. Revenue dropped by 32.55% YoY, net income fell by 36.49% YoY, and EPS declined by 59.06% YoY. No recent news or significant insider activity to drive positive sentiment.
In Q3 2025, revenue declined to $5,007,000 (-32.55% YoY), net income dropped to -$9,277,230 (-36.49% YoY), and EPS fell to -2.96 (-59.06% YoY). Gross margin improved to 60.22% (+15.30% YoY), but overall financial performance remains weak.
No data available on analyst ratings or price target changes.
